Arrowhead Pharmaceuticals, Inc. announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-2 study in patients with severe hypertriglyceridemia (SHTG), which was published in JAMA Cardiology, and the Phase 2 MUIR study in patients with mixed hyperlipidemia, which was published in the New England Journal of Medicine. Plozasiran is currently being investigated in the PALISADE Phase 3 clinical study in patients withFCS, which recently completed, SHASTA-3,4,5 Phase 3 studies in patients with SHTG, and an upcoming CAPITAN Phase 3 study in patients with mixed hyper lipoproteins.

Plozasiran has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Drug Designation by the European Medicines Agency. In addition, any statements that refer to projections of future financial performance, trends in business, expectations for product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of collaborations with other companies, or other characteristics of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of preclinical studies and clinical trials, and the timing thereof, the duration and impact of regulatory delays in clinical programs, the ability to finance operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of scientific studies, ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our product pipeline or product candidates, and the potential regulatory approvals and the timing thereof, the period and impact of regulatory delays in our clinical programs, the likelihood and timing of The receipt of future milestone and licensing costs, the future success of our scientific studies, the ability to successfully develop and commercializing drug candidates, the timing for start and completing clinical trials, rapid technology change in our markets, the Enforcement of our product pipeline or product candidate.